HomeElements

Blog Layouts

OUR NEWSMasonry Post Grid

AllBiologicsCorporateDiagnosticsDiscoveryNewsOphthalmicsTherapeutics

OUR NEWSLatest Posts

Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
27 July 2023
Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
25 July 2023
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
Verséa Health and iRemedy Announce Strategic Joint Venture
28 June 2023
Verséa Health and iRemedy Announce Strategic Joint Venture

Subscribe to the Verséa Membership Club

Receive exclusive membership offers, discounts and latest industry insights, free of charge.

Subscribe to the Verséa Membership Club

Receive exclusive membership offers, discounts and latest industry insights, free of charge.
[hubspot type=form portal=20074237 id=4147b977-36b5-4704-8428-ecd033cf2203]
https://www.versea.com/wp-content/uploads/2021/02/new_logo.png
1-800-397-0670
Contact Us
401 S. Florida Ave, Tampa, FL 33602

© 2022 Verséa Health, Inc. All rights reserved.

Explore Verséa

News